<DOC>
	<DOCNO>NCT01093820</DOCNO>
	<brief_summary>Hypothesis : Based available pharmacokinetic data healthy volunteer hypothesize administration cumulative dose 210μg continuous erythropoietin receptor activator , Mircera® ( Roche ) , 3 month post percutaneous coronary intervention ( PCI ) result hemoglobin ( Hb ) level &gt; 15 g/dl patient ST-segment elevation myocardial infarction ( STEMI ) Design : Prospective , open label single center pilot study</brief_summary>
	<brief_title>Hemoglobin Kinetics Response Mircera® Patients With Acute Myocardial Infarction</brief_title>
	<detailed_description>This pilot trial include 8 patient . The inclusion 8 patient allow perform representative statistic expect Hb kinetics response Mircera® .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Patients ( age 18 80 year ) acute STEMI undergo PCI Main Hemoglobin level &gt; 15g/dL history myeloproliferative syndrome thrombolysis index infarction anticipate additional revascularization within 3 month cardiogenic shock</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>acute myocardial infarction</keyword>
	<keyword>continuous erythropoetin receptor activator</keyword>
	<keyword>Mircera</keyword>
	<keyword>hemoglobin kinetics</keyword>
</DOC>